InMed Pharmaceuticals Inc.

DB:MWG

Kanada / Sağlık Hizmetleri / İlaç

Genel Bakış

Haberler

10 Yıllık Finansal Veriler

Hisse Fiyatı

1,84 EUR


Key Metrics	Latest
Total Revenue	4,832 M
Adjusted EBITDA	-7,548 M
EBITDA Margin	-156,2%
Net Profit Margin	-163,8%
Total Assets	8,502 M
Total Debt	948,959 K

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Jun-15	Jun-16	Jun-17	Jun-18	Jun-19	Jun-20	Jun-21	Jun-22	Jun-23	Jun-24	12 Months

Revenue	0	0	0	0	0	0	0	1	4	5	5
% Growth		NA	NA	NA	NA	NA	NA	NA	279.6%	11.2%

Adjusted EBITDA	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(13)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1230.6%	-197.7%	-172.1%	-156.2%

Adjusted EBIT	(3)	(2)	(3)	(7)	(10)	(9)	(10)	(14)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1247.6%	-202.6%	-176.9%	-160.7%

Adjusted Net Income	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(15)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1368.6%	-192.2%	-166.9%	-163.8%

Adjusted Basic EPS	NA	NA	NA	NA	(977.39)	(856.16)	(759.16)	(531.71)	(64.92)	(20.14)	(10.42)

Destekleyen Hesaplamalar

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Original
USD	Fiscal Year Ending										Latest
(in millions)	Jun-15	Jun-16	Jun-17	Jun-18	Jun-19	Jun-20	Jun-21	Jun-22	Jun-23	Jun-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	0	0	0	0	0	0	0	1	4	5	5
% Growth	NA	NA	NA	NA	NA	NA	NA	NA	279.6%	11.2%

Cost of Revenue	0	0	0	0	0	0	0	(1)	(3)	(3)	(3)
Gross Profit	0	0	0	0	0	0	0	1	1	1	2
% Revenue	NA	NA	NA	NA	NA	NA	NA	49.9%	33.9%	23.9%	35.4%

Research and Development	(1)	(0)	(1)	(1)	(4)	(6)	(5)	(7)	(4)	(4)	(4)
Selling and Marketing	0	0	0	0	0	0	0	0	0	0	0
General and Admin	(3)	(1)	(3)	(5)	(6)	(3)	(4)	(7)	(6)	(5)	(6)
Other Inc / (Exp)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(5)	(0)	(0)	(0)
Total Operating Exp	(3)	(2)	(3)	(7)	(10)	(9)	(10)	(19)	(10)	(9)	(10)

Operating Income	(3)	(2)	(3)	(7)	(10)	(9)	(10)	(19)	(8)	(8)	(8)
% Revenue	NA	NA	NA	NA	NA	NA	NA	-1716.1%	-203.8%	-178.3%	-162.8%

Interest Expense	0	0	0	0	0	0	0	0	0	1	(0)
Pre-tax Income	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(19)	(8)	(8)	(8)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0	(0)	(0)	(0)
Net Income to Company	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(19)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1707.3%	-192.2%	-166.9%	-163.8%

Minority Interest in Earnings	0	0	0	0	0	0	0	0	0	0	0
Net Income to Stockholders	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(19)	(8)	(8)	(8)

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(19)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1707.3%	-192.2%	-166.9%	-163.8%

As Reported
Basic EPS (Continuing Ops)	0.00	0.00	0.00	0.00	(977.39)	(856.16)	(759.16)	(663.32)	(64.92)	(20.14)	(12.37)
Diluted EPS (Continuing Ops)	0.00	0.00	0.00	0.00	(977.39)	(856.16)	(759.16)	(663.32)	(64.92)	(20.14)	(12.37)

WA Basic Shares Out.	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.03	0.12	0.38	0.76
WA Diluted Shares Out.	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.03	0.12	0.38	0.76

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(19)	(8)	(8)	(8)
Addback: Net Interest Expense	0	0	0	(0)	(0)	(0)	(0)	(0)	(0)	(1)	0
Addback: Other Non Operating Expenses, Total	0	0	0	(0)	0	(0)	0	0	0	0	0
Addback: Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0	0
Addback: Restructuring Charges	0	0	0	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	2	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	1	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	1	0	0	0
Adjusted EBITDA	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(13)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1230.6%	-197.7%	-172.1%	-156.2%

Adjusted EBIT	(3)	(2)	(3)	(7)	(10)	(9)	(10)	(14)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1247.6%	-202.6%	-176.9%	-160.7%

Adjusted Net Income Reconciliation
Net Income to Company	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(19)	(8)	(8)	(8)
Addback: Unusual Items	0	0	0	0	0	0	0	5	0	0	0
Less: Tax Benefit of Unusual Items (26%)	0	0	0	0	0	0	0	(1)	0	0	0
Adjusted Net Income	(3)	(2)	(3)	(6)	(10)	(9)	(10)	(15)	(8)	(8)	(8)
% Margin	NA	NA	NA	NA	NA	NA	NA	-1368.6%	-192.2%	-166.9%	-163.8%

Yüklenme Hatası

InMed Pharmaceuticals Inc.

DB:MWG

Kanada / Sağlık Hizmetleri / İlaç

10 Yıllık Finansal Veriler